Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/25/22
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH PatientsGlobeNewsWire • 02/08/22
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/14/22
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual ConferenceGlobeNewsWire • 11/26/21
Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a BetZacks Investment Research • 11/17/21
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of TreatmentGlobeNewsWire • 11/12/21
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/21
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASHGlobeNewsWire • 10/19/21
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor ConferenceGlobeNewsWire • 10/05/21
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/21
Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of TreatmentBenzinga • 07/08/21
Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of TreatmentGlobeNewsWire • 07/08/21
Akero Therapeutics Presents at the American Diabetes Association's 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-GlobeNewsWire • 06/25/21
Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH PatientsBenzinga • 06/21/21
Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASHGlobeNewsWire • 06/21/21
Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?Zacks Investment Research • 06/09/21
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/21
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort CGlobeNewsWire • 03/22/21